Read Our Investor Brief on Teva Pharmaceutical Industries

Shares of Healthcare sector company Teva Pharmaceutical Industries moved -2.5% today, and are now trading at a price of $8.74. The large-cap stock's daily volume was 8,308,718 compared to its average volume of 9,385,170. The S&P 500 index returned a 0.6% performance.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company is based in Tel Aviv and has 34,713 full time employees. Its market capitalization is $9,905,549,312.

10 analysts are following Teva Pharmaceutical Industries and have set target prices ranging from $7 to $13 per share. On average, they have given the company a rating of hold. At today's prices, TEVA is trading -10.77% away from its average analyst target price of $9.8 per share.

Over the last year, TEVA's share price has increased by 3.3%, which represents a difference of 18.2% when compared to the S&P 500. The stock's 52 week high is $11.34 per share whereas its 52 week low is $6.78. With an average free cash flow of $723,000,000.0 that have been growing at an average rate of 11.8% over the last four years, Teva Pharmaceutical Industries is in a position to continue its strong stock performance trend.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS